Revefenacin in Acute Respiratory Insufficiency in COPD
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating
the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in
patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.